Australia markets closed

Nicox S.A. (NICXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.44000.0000 (0.00%)
At close: 01:11PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.4400
Open0.4400
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.4400 - 0.4400
52-week range0.4400 - 0.6400
Volume100
Avg. volume0
Market cap22.132M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-0.4000
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Number of voting rights as of April 30, 2023

    Nicox SA Société anonyme with a registered capital of € 50,156,698 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On May 3, 2023, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) As of April 30, 2023 Total number of shares composing the share capital 50,156,698Total

  • GlobeNewswire

    Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China

    Press ReleaseNicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox’s partner, Ocumension Therapeutics, announced on April 26, 2023, that they had received Priority Review Status for the New Drug Application for ZERVIATE in ChinaAccelerates the ZERVIATE® approval and launch, which are expected in China in 2024 April 28, 2023 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an internati

  • GlobeNewswire

    Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023

    Press Release Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023 April 26, 2023 – release at 9:00 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the transfer of the listing of the securities issued by the Company from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility (the “Transfer”), will be effective as from the tra